海创药业HP515临床II期试验完成首批参与者入组

Core Viewpoint - Haichuang Pharmaceutical has announced the completion of the first batch of participant enrollment for its clinical phase II trial of HP515, a drug developed for the treatment of Metabolic Associated Steatotic Liver Disease (MASH), previously known as Non-Alcoholic Steatohepatitis (NASH) [1] Company Summary - The clinical phase II trial for HP515 has recently completed its first batch of participant enrollment [1] - As of the announcement date, there are no similar targeted products approved for market in China [1]